share_log

Victory Capital Management Inc. Raises Stock Position in Enovis Co. (NYSE:ENOV)

Victory Capital Management Inc. Raises Stock Position in Enovis Co. (NYSE:ENOV)

胜利资本管理公司提高了Enovis Co的股票头寸（纽约证券交易所代码：ENOV）
Defense World ·  2023/01/25 06:11

Victory Capital Management Inc. lifted its position in Enovis Co. (NYSE:ENOV – Get Rating) by 0.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 416,342 shares of the company's stock after buying an additional 2,360 shares during the period. Victory Capital Management Inc. owned approximately 0.77% of Enovis worth $19,181,000 as of its most recent SEC filing.

胜利资本管理公司在最近提交给美国证券交易委员会的文件中说，该公司在第三季度将其在Enovis Co.(NYSE：ENOV-GET评级)的持仓提高了0.6%。该基金持有该公司416,342股股票，在此期间又购买了2,360股。截至最近提交给美国证券交易委员会的文件，胜利资本管理公司持有Enovis约0.77%的股份，价值19,181,000美元。

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Wipfli Financial Advisors LLC purchased a new stake in Enovis during the 3rd quarter worth approximately $36,000. M&T Bank Corp purchased a new stake in Enovis during the 2nd quarter worth approximately $137,000. Paloma Partners Management Co purchased a new stake in shares of Enovis in the 2nd quarter valued at $209,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Enovis in the 2nd quarter valued at $261,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Enovis in the 2nd quarter valued at $285,000. Hedge funds and other institutional investors own 96.73% of the company's stock.

其他一些机构投资者和对冲基金最近也调整了对该公司的持股。Wipfli Financial Advisors LLC在第三季度购买了Enovis的新股份，价值约3.6万美元。M&T Bank Corp在第二季度购买了Enovis的新股份，价值约13.7万美元。Paloma Partners Management Co在第二季度购买了价值20.9万美元的Enovis新股。康纳·克拉克和伦恩投资管理有限公司在第二季度购买了价值261,000美元的Enovis新股。最后，Zurcher Kantonalbank苏黎世广东银行在第二季度购买了价值28.5万美元的Enovis新股。对冲基金和其他机构投资者持有该公司96.73%的股票。

Get
到达
Enovis
伊诺维斯
alerts:
警报：

Analyst Upgrades and Downgrades

分析师升级和下调评级

Several analysts have recently commented on ENOV shares. Evercore ISI upped their price objective on shares of Enovis to $68.00 in a report on Tuesday, January 3rd. The Goldman Sachs Group initiated coverage on shares of Enovis in a research report on Tuesday, October 11th. They set a "buy" rating and a $57.00 price objective for the company. Jefferies Financial Group initiated coverage on shares of Enovis in a report on Wednesday, October 12th. They set a "buy" rating and a $60.00 target price for the company. Robert W. Baird dropped their target price on shares of Enovis from $73.00 to $68.00 and set an "outperform" rating for the company in a report on Thursday, November 3rd. Finally, TheStreet lowered shares of Enovis from a "c" rating to a "d" rating in a report on Wednesday, November 2nd. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $63.50.

几位分析师最近对ENOV的股票发表了评论。在1月3日星期二的一份报告中，Evercore ISI将Enovis的股价目标上调至68.00美元。10月11日，星期二，高盛在一份研究报告中首次对依诺维斯的股票进行了报道。他们为该公司设定了“买入”评级和57.00美元的目标价。杰富瑞金融集团在10月12日星期三的一份报告中启动了对Enovis股票的报道。他们为该公司设定了“买入”评级和60.00美元的目标价。罗伯特·W·贝尔德在11月3日星期四的一份报告中将Enovis的股票目标价从73.00美元下调至68.00美元，并为该公司设定了“跑赢大盘”的评级。最后，华尔街在11月2日星期三的一份报告中将Enovis的股票评级从C级下调至D级。两名研究分析师对该股的评级为持有，七名分析师对该股的评级为买入。根据MarketBeat的数据，该股目前的共识评级为“适度买入”，共识目标价为63.50美元。

Insider Transactions at Enovis

Enovis的内幕交易

In related news, CFO Christopher M. Hix sold 1,367 shares of the business's stock in a transaction dated Wednesday, December 14th. The shares were sold at an average price of $55.28, for a total value of $75,567.76. Following the completion of the transaction, the chief financial officer now owns 44,605 shares of the company's stock, valued at approximately $2,465,764.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at
在相关新闻中，首席财务官克里斯托弗·M·希克斯在12月14日星期三的一笔交易中出售了1,367股该公司的股票。这些股票的平均价格为55.28美元，总价值为75,567.76美元。交易完成后，首席财务官现在拥有该公司44,605股股票，价值约2,465,764.40美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可在
the SEC website
美国证券交易委员会网站
. In other Enovis news, EVP Daniel A. Pryor sold 67,421 shares of Enovis stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $54.58, for a total value of $3,679,838.18. Following the completion of the sale, the executive vice president now owns 75,731 shares in the company, valued at approximately $4,133,397.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through
。在Enovis的其他消息中，执行副总裁Daniel·A·普赖尔在11月15日星期二的交易中出售了67,421股Enovis股票。这只股票的平均售价为54.58美元，总价值为3,679,838.18美元。出售完成后，执行副总裁总裁现在拥有该公司75,731股股份，价值约4,133,397.98美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，可以通过以下方式获取
this link
这个环节
. Also, CFO Christopher M. Hix sold 1,367 shares of the business's stock in a transaction dated Wednesday, December 14th. The stock was sold at an average price of $55.28, for a total value of $75,567.76. Following the sale, the chief financial officer now owns 44,605 shares of the company's stock, valued at approximately $2,465,764.40. The disclosure for this sale can be found
。此外，首席财务官克里斯托弗·M·希克斯在日期为12月14日(星期三)的交易中出售了1,367股该公司股票。这只股票的平均售价为55.28美元，总价值为75567.76美元。出售后，首席财务官现在拥有44,605股公司股票，价值约2,465,764.40美元。关于这次销售的披露可以找到
here
这里
. Corporate insiders own 8.30% of the company's stock.
。公司内部人士持有该公司8.30%的股份。

Enovis Trading Down 0.7 %

Enovis股价下跌0.7%

ENOV stock opened at $60.54 on Wednesday. The stock has a market cap of $3.28 billion, a P/E ratio of 126.13 and a beta of 1.99. The company's 50 day moving average is $55.55 and its two-hundred day moving average is $53.44. Enovis Co. has a twelve month low of $43.88 and a twelve month high of $129.70.

周三，ENOV的股票开盘报60.54美元。该股市值为32.8亿美元，市盈率为126.13，贝塔系数为1.99%。该公司50日移动均线切入位在55.55美元，200日移动均线切入位在53.44美元。Enovis Co.股价跌至43.88美元的12个月低点，以及129.70美元的12个月高点。

Enovis (NYSE:ENOV – Get Rating) last posted its quarterly earnings data on Wednesday, November 2nd. The company reported $0.59 earnings per share for the quarter, beating analysts' consensus estimates of $0.47 by $0.12. Enovis had a net margin of 0.94% and a return on equity of 4.46%. The firm had revenue of $383.81 million for the quarter, compared to analyst estimates of $379.75 million. On average, equities research analysts predict that Enovis Co. will post 2.24 earnings per share for the current year.

Enovis(纽约证券交易所代码：ENOV-GET Rating)最近一次公布季度收益数据是在11月2日星期三。该公司公布本季度每股收益为0.59美元，比分析师普遍预期的0.47美元高出0.12美元。Enovis的净利润率为0.94%，股本回报率为4.46%。该公司本季度营收为3.8381亿美元，而分析师预期为3.7975亿美元。股票研究分析师平均预测，Enovis Co.本年度每股收益将达到2.24欧元。

Enovis Company Profile

Enovis公司简介

(Get Rating)

(获取评级)

Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries.

Enovis公司是一家全球性的医疗技术公司。该公司开发、制造和分销医疗器械产品，供整形外科专家、外科医生、初级保健医生、疼痛管理专家、物理治疗师、足科医生、脊椎按摩师、运动训练师和其他医疗保健专业人员使用，以治疗因退行性疾病、畸形、创伤事件和运动相关伤害而导致的肌肉骨骼疾病患者。

Featured Articles

专题文章

  • Get a free copy of the StockNews.com research report on Enovis (ENOV)
  • Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
  • How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
  • Is the Pain Over for Baudax Bio Investors after a 70% Spike?
  • Will Rocket Lab's First U.S. Launch Send Stock Into Stratosphere?
  • Is It Time To Get Aggressive With Defense Stocks?
  • 免费获取StockNews.com关于Enovis的研究报告(ENOV)
  • 柔顺治疗公司的差距增加了34%：未来还会有更多的好处吗？
  • 2023年初裁员将如何影响这5只生物科技股？
  • Baudax Bio投资者在经历了70%的飙升后，痛苦是否已经结束？
  • 火箭实验室的首次美国发射将把斯托克送入平流层吗？
  • 现在是时候积极投资国防类股了吗？

Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.

接受《Enovis Daily》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Enovis和相关公司的最新新闻和分析师评级的每日简要摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发